Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The object of this study is to compare the rate and extent of absorption of an
investigational formulation of buprenorphine 8 mg sublingual tablets manufactured by Barr
Laboratories, Inc. to an equivalent oral dose of the commercially available reference
product, Subutex® manufactured by Reckitt Benckiser, following and overnight fast of at least
10 hours.